Quercetin, Menadione, Doxorubicin combination as a potential alternative to Doxorubicin monotherapy of acute lymphoblastic leukemia

[1] Baran I, Cell proliferation versus apoptosis. Mechanisms and particularities under genotoxic or oxidative stress conditions. “Carol Davila” University Publishing House, Bucharest, 2014Search in Google Scholar

[2] Murakami A,Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett 2008;269:315-2510.1016/j.canlet.2008.03.04618467024Search in Google Scholar

[2] Baran I, Ganea C, Privitera S, Scordino A, Barresi V, Musumeci F, et. al. Detailed analysis of apoptosis and delayed luminescence of human leukemia Jurkat T cells after proton-irradiation and treatments with oxidant agents and flavonoids. Oxid Med Cell Longev. 2012;2012:498914. doi:10.1155/2012/49891410.1155/2012/498914339721022829956Search in Google Scholar

[3] Baran I, Ionescu D, Filippi A, Mocanu M.M., Iftime A., Babes R., Tofolean I.T., Irimia R., Goicea A., Popescu V., Dimancea A., Neagu A., Ganea C., 2014. Novel insights into the antiproliferative effects and synergism of quercetin and menadione in human leukemia Jurkat T cells. Leuk Res. 2014;38(7):836-49.10.1016/j.leukres.2014.04.01024862793Search in Google Scholar

[4] De Marchi U, Biasutto L, Garbisa S, Toninello A, Zoratti M. Quercetin can act either as an inhibitor or an inducer of the mitochondrial permeability transition pore: a demonstration of the ambivalent redox character of polyphenols. Biochim Biophys Acta. 2009;1787(12):1425-32.10.1016/j.bbabio.2009.06.00219523917Search in Google Scholar

[5] Baran I, Ionescu D, Privitera S, Scordino A, Mocanu MM, Musumeci F, Grasso R, Gulino M, Iftime A, Tofolean IT, Garaiman A, Goicea A, Irimia R, Dimancea A, Ganea C. Mitochondrial respiratory Complex I probed by delayed luminescence spectroscopy. JBO numele complet 2013;18(12):127006.10.1117/1.JBO.18.12.12700624365956Search in Google Scholar

[6] http://chemoth.com/types/antracyclinesSearch in Google Scholar

[7]Jeong JH, An Jy, Kwon YT, Rhee JG, Lee YJ.Effects of low dose quercetin:cancer specific inhibition of cell cycle progression.J Cell Biochem 2009;106:73-8210.1002/jcb.21977273662619009557Search in Google Scholar

[8] Yen GC, Duh PD, Tsai HL, Huang SL. Pro-oxidative properties of flavonoids in human lymphocytes.Biosci Biotechnol Biochem 2003;67:1215-2210.1271/bbb.67.121512843645Search in Google Scholar

[9] Du G, Lin H, Wang M et al.Quercetin greatly improved therapeutic index of doxorubicin against 4T1 brest cancer by its apposite effect on HIF-1α in tumor and normal cells.Cancer Chemother Pharmacol 2010;65:277-8710.1007/s00280-009-1032-719466611Search in Google Scholar

[10]Wang G,Zhang J, Liu L,Sharma S,Dong Q, Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl.PLos One 2012;7:e5176410.1371/journal.pone.0051764351988623240061Search in Google Scholar

[11]Thorn C,Oshiro C,Altman R.B.Doxorubicin pathways:pharmacodynamics and adverse effects,Pharmacogenics and genomicsSearch in Google Scholar

[12]http://elifesciences.org/content/elife/1/e00387.full.pdfSearch in Google Scholar

[13]Denard B,Lee C,Ye J 2012.Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1.eLife 1 e0009010.7554/eLife.00090352464923256041Search in Google Scholar

[14] Baran I. et al., Cell Biochem. Biophys. 2010; 58:169-179Search in Google Scholar

[15] Baran I. et al., Leukemia Res. 2014; 38:836-84910.1016/j.leukres.2014.04.01024862793Search in Google Scholar

[16] Belizario JE, Alves J, Occhiucci JM, Garay-Malpartida M, Sesso A. A mechanistic view of mitochondrial death decision pores. Brazilian Journal of Medical and Biological Research. 2007;40:1011-24.10.1590/S0100-879X200600500010917665037Search in Google Scholar

[17] Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, Bertoncelli L, Cooper EL, Cossarizza A. Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med. 2011;2011:591356.10.1093/ecam/neq053313671121792362Search in Google Scholar

[18] Ferry DR,Smith A,Malkhandi J, at al. Phase 1 clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vitro tyrosine kinase inhibition.Clin Cancer Res 1996;2:659-68Search in Google Scholar

[19] Am J Clin Nutr Oct 1, 2001, vol 74, no 4 418-42510.7861/clinmedicine.1-5-418Search in Google Scholar

[20] Rice s.a., 2003; Loke s.a., 2008; Kanadaswami s.a., 2005 Search in Google Scholar